S. Loibl

1.5k total citations
30 papers, 516 citations indexed

About

S. Loibl is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Loibl has authored 30 papers receiving a total of 516 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Reproductive Medicine and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Loibl's work include Ovarian cancer diagnosis and treatment (11 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (5 papers). S. Loibl is often cited by papers focused on Ovarian cancer diagnosis and treatment (11 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (5 papers). S. Loibl collaborates with scholars based in Germany, United States and France. S. Loibl's co-authors include Jens Huober, Gϋnter von Minckwitz, Barbara Schmalfeldt, Valentina Nekljudova, Hans‐Joachim Lück, Andreas du Bois, Carsten Denkert, Michael Untch, M. Gropp and Christos Sotiriou and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

S. Loibl

30 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Loibl Germany	10	254	227	146	123	96	30	516
Ingirídur Skírnisdóttir Sweden	16	234 0.9×	499 2.2×	77 0.5×	77 0.6×	107 1.1×	26	682
C O'Flaherty United States	6	187 0.7×	149 0.7×	117 0.8×	90 0.7×	43 0.4×	8	430
Linn Woelber Germany	14	150 0.6×	299 1.3×	133 0.9×	46 0.4×	90 0.9×	23	479
Alessandra Bologna Italy	12	288 1.1×	188 0.8×	50 0.3×	74 0.6×	62 0.6×	37	421
Christopher DiSimone United States	6	271 1.1×	133 0.6×	71 0.5×	148 1.2×	85 0.9×	10	490
Ulrich Canzler Germany	13	226 0.9×	528 2.3×	303 2.1×	80 0.7×	34 0.4×	48	683
Josep M. del Campo Spain	10	187 0.7×	261 1.1×	62 0.4×	78 0.6×	51 0.5×	20	439
Kim McManus United States	9	107 0.4×	134 0.6×	100 0.7×	69 0.6×	126 1.3×	10	396
Jeffrey C. Goh Australia	11	167 0.7×	167 0.7×	35 0.2×	91 0.7×	39 0.4×	35	376
Alejandro Rojo‐Sebastián Spain	14	122 0.5×	142 0.6×	75 0.5×	88 0.7×	114 1.2×	18	686

Countries citing papers authored by S. Loibl

Since Specialization

Citations

This map shows the geographic impact of S. Loibl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Loibl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Loibl more than expected).

Fields of papers citing papers by S. Loibl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Loibl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Loibl. The network helps show where S. Loibl may publish in the future.

Co-authorship network of co-authors of S. Loibl

This figure shows the co-authorship network connecting the top 25 collaborators of S. Loibl. A scholar is included among the top collaborators of S. Loibl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Loibl. S. Loibl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Loibl, S., Michael Untch, Jens Huober, et al.. (2025). 292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Long-term analysis from the GeparNuevo trial. Annals of Oncology. 36. S303–S304. 1 indexed citations

Loibl, S., Carolyn J. Henry, Giovanni Tomasello, et al.. (2025). LBA1 Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: Final analysis at 11.3 years’ median follow-up. ESMO Open. 10. 105112–105112. 1 indexed citations

Denk, Dominic, Anurag Singh, Herbert G. Kasler, et al.. (2025). Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging. 5(11). 2309–2322. 2 indexed citations

Putz, Florian, Chiara Corti, Wolfgang Janni, et al.. (2025). Artificial intelligence as treatment support in breast cancer: current perspectives. The Breast. 83. 104564–104564. 1 indexed citations

Hamilton, Erika, S. Loibl, Thomas Bachelot, et al.. (2025). CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer. Future Oncology. 21(7). 795–806. 1 indexed citations

Laakmann, Elena, Elisa Agostinetto, Francesco Schettini, et al.. (2023). 208P Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases: A subanalysis of the German brain metastases in breast cancer registry (BMBC). ESMO Open. 8(1). 101397–101397. 1 indexed citations

Reinisch, Mattea, Jens‐Uwe Blohmer, Theresa Link, et al.. (2022). 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC). Annals of Oncology. 33. S166–S167. 1 indexed citations

Laakmann, Elena, Tanja Neunhöffer, Rudolf Weide, et al.. (2022). 170P Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Annals of Oncology. 33. S202–S203. 1 indexed citations

Schmidt, Marcus, Kristina Lübbe, Thomas Decker, et al.. (2022). A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE). ESMO Open. 7(6). 100601–100601. 8 indexed citations

10.

Loibl, S., Ian J. Majewski, Valentina Guarneri, et al.. (2016). PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Annals of Oncology. 27(8). 1519–1525. 146 indexed citations

11.

Blank, Patricia R., S. Loibl, Barbro Linderholm, et al.. (2015). Cost-effectiveness analysis of VEGF-A testing to predict response to bevacizumab (BEV) as a component of neo-adjuvant therapy of early HER-2 negative breast cancer. Annals of Oncology. 26. iii15–iii15. 1 indexed citations

12.

Branstetter, Daniel, Blake Mergler, S. Loibl, et al.. (2013). Abstract P1-08-25: RANK expression is prognostic and predictive in primary breast carcinoma: Analysis of samples from the GeparTrio study. Cancer Research. 73(24_Supplement). P1–8. 2 indexed citations

13.

Baumann, Klaus, Jacobus Pfisterer, Pauline Wimberger, et al.. (2011). Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group. Gynecologic Oncology. 123(1). 27–32. 42 indexed citations

14.

Harter, P, Maik Hahmann, Hans-Joachim Lueck, et al.. (2009). Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis. Annals of Surgical Oncology. 16(5). 1324–1330. 93 indexed citations

15.

Stengel, Dirk, Andreas du Bois, Susanne Markmann, et al.. (2007). Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO). Journal of Clinical Oncology. 25(18_suppl). 5526–5526. 6 indexed citations

16.

duBois, Andreas, Jens Huober, S. Loibl, et al.. (2006). Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)☆. Gynecologic Oncology. 105(1). 132–137. 67 indexed citations

17.

Pfisterer, Jacobus, Philipp Harter, Ulrich Canzler, et al.. (2005). The role of surgery in recurrent ovarian cancer. International Journal of Gynecological Cancer. 15(s3). 195–198. 35 indexed citations

18.

Loibl, S., Vincent Farines, Gϋnter von Minckwitz, et al.. (2005). Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 – estrogen has an influence on e-NOS, but not on i-NOS. Pathology - Research and Practice. 202(1). 1–7. 19 indexed citations

19.

Loibl, S., et al.. (2004). Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study. Anti-Cancer Drugs. 15(7). 719–724. 13 indexed citations

20.

Loibl, S., G von Minckwitz, & M. Kaufmann. (2002). Adjuvant hormone therapy following primary therapy for endometrial cancer. European Journal of Cancer. 38. 41–43. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact